Research Article

[Retracted] Prognostic Factor Study of Macular Edema Recurrence in Retinal Vein Occlusion after Conbercept Treatment: A Post Hoc Analysis of the FALCON Study

Table 2

Clinical measurements comparisons of the study eyes between the recurrence group and nonrecurrence group.

FeaturesRecurrence group ()Nonrecurrence group () value

Disease type
 BRVO, (%)17 (44.74%)13 (61.90%)0.32
 CRVO, (%)21 (55.26%)8 (38.10%)
BCVA (ETDRS letters), median (IQR)59 (25)57 (11)0.32
CRT, median (IQR)634.5 (207)573.0 (195)0.07
MV, median (IQR)13.04 (4.41)11.41 (3.25)0.01
Irregular FAZ contours, (%)24 (63.16%)11 (52.38%)0.75
NP
 No NP, (%)10 (26.32%)4 (19.05%)0.003
 <5 PD, (%)7 (18.42%)6 (28.57%)0.18
 >5 PD, (%)16 (42.11%)10 (47.62%)0.003
 Unevaluable, (%)5 (13.16%)1 (4.76%)0.47
Macular hemorrhage, (%)8 (21.05%)2 (9.52%)0.47
EZ
 Intact, (%)8 (21.05%)5 (23.81%)0.099
 Disruption in the fovea, (%)14 (36.84%)14 (66.67%)0.03
 Disruption in the parafovea, (%)5 (13.16%)1 (4.76%)0.41
 Unevaluable, (%)11 (28.95%)1 (4.76%)0.04
DRIL
 No, (%)19 (50.00%)14 (66.67%)0.27
 Yes, (%)15 (39.47%)5 (23.81%)<0.001
 Unevaluable, (%)4 (10.53%)2 (9.52%)0.99
OLM
 Intact, (%)10 (26.32%)6 (28.57%)0.99
 Disruption in the fovea, (%)11 (28.95%)13 (61.90%)0.02
 Disruption in the parafovea, (%)7 (18.42%)1 (4.76%)0.23
 Unevaluable, (%)10 (26.32%)1 (4.76%)0.08
IRF
 No IRF, (%)0 (0%)1 (4.76%)0.36
 Macula area, (%)5 (13.16%)6 (28.57%)0.17
 Paramacular area, (%)2 (5.26%)1 (4.76%)0.99
 CME, (%)31 (81.58%)13 (61.90%)0.12
SRF
 No SRF, (%)11 (28.95%)7 (33.33%)0.77
 Small amount, (%)21 (55.26%)11 (52.38%)0.99
 Large amount, (%)6 (15.79%)3 (14.29%)0.99

IQR: interquartile range; BCVA: best-corrected visual acuity; CRT: central retina thickness; MV: macular volume; FAZ: foveal avascular zone; NPA: nonperfusion area; PD: papilla diameter; HE: hard exudates; EZ: ellipsoid zone; OLM: outer limiting membrane; DRIL: disorganization of retinal inner layers; IRF: intraretinal fluid; CME: cystoid macular edema; SRF: subretinal fluid.